Theriva Biologics Reports Q2 2026 Financial Results

What Happened
Theriva Biologics, Inc. (TOVX), a Nevada corporation, filed a Form 8-K on August 11, 2026 (Item 2.02) to announce that it issued a press release containing financial information for the quarter ended June 30, 2026. The press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: August 11, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended June 30, 2026.
• Exhibit: Press release with the financial information is attached as Exhibit 99.1.
• Interactive data: Cover Page Interactive Data File included (Exhibit 104, XBRL).

Why It Matters
The 8-K signals that Theriva has released its latest quarterly operating and financial data — information investors use to assess recent revenue, expenses, cash position, and operational progress. Review the attached press release (Exhibit 99.1) for specific figures and management commentary; those details can affect short-term trading and longer-term views of the company’s financial health.